However, it failed to reach significance with respect to the difference in the proportions of participants in the two groups showing ≥20% improvement in PANSS (Positive and Negative Syndrome Scale) total score.
← all excerpts
Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia.
1
—
—